Patients with hepatic insufficiency is an important subgroup of who receive EGFR TKIs. Phase I/II studies showed that Icotinib has good security. Based on the above considerations, this single-arm, open-label study is designed to evaluate the safety of icotinib 125mg three times daily for histologically or cytologically confirmed NSCLC patients with hepatic insufficiency.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed diagnosis of IIIB/IV stage NSCLC patients who are not suitable for surgery or radiotherapy
ECOG performance status points (PS) is 0-2
Liver function:
A (mild hepatic dysfunction):
A1) total bilirubin within normal limit (ULN), while AST\> ULN;
A2) total bilirubin within1.0-1 .5 × ULN;
B (moderate hepatic dysfunction): total bilirubin within1.5-3 .0 × ULN
No malabsorption or other gastrointestinal disorders effecting drug absorption
Life expectancy: more than 12 weeks.
You may not be if
Previous usage of HER/EGFR inhibitors or other target molecule drugs ( small molecule drugs or monoclonal antibody therapy )
Patients requires liver shunt , stent placement, or radiotherapy when 2 weeks before the start of the study or research process .